“This unique public-private collaboration provides funding for HIV Cure Center and Qura Therapeutics, the joint venture that brings academic and pharmaceutical research scientists together for the goal of curing people with HIV. David Margolis, MD, is the director of the UNC Cure Center.

ViiV Healthcare and the University of North Carolina at Chapel Hill announced today a five-year, $20 million renewal of a unique, public-private research partnership solely focused on discovering a cure for HIV. ViiV is a global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders.”

This story first appeared March 9, 2020 on the UNC Health and School of Medicine Newsroom.